Ladenburg ups Avadel Pharma PT to $20 from $14


Ladenburg Thalmann raised its price target for Avadel Pharmaceuticals (NASDAQ:AVDL) to $20 from $14 after the company posted positive topline Phase 3 results for FT218, a once nightly formulation of Micropump controlled-released sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. The stock closed at $11.15 on April 27.

Based on the positive results reported, this could support an NDA under the 505(b)(2) pathway in the second half of 2020, with potential approval by mid-2021, writes analyst Matthew Kaplan. “If approved, we believe FT218 will likely provide a significant improvement for patients [including improved compliance] over the current standard-of-care,” he added.

Mr. Kaplan said the company is enrolling an open-label extension and switching study to maximize the potential of FT218 and is preparing pre-commercial activities for FT218, such as a medical communication plan and market access study.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.